Ironwood Pharmaceuticals develops and commercializes treatments for gastrointestinal and rare diseases. Its principal commercial product, LINZESS (linaclotide), treats certain constipation-related conditions and is commercialized in the United States with AbbVie; it is also involved in the development of apraglutide for short bowel syndrome with intestinal failure. Revenue is centered on collaboration and licensing economics related to its therapies.
Ironwood Pharmaceuticals Inc. (IRWD) has a MarketKingdoms composite score of 76.6 (A-), an A-range rating. It ranks 22nd of 1,866 covered companies, 1st of 78 in Healthcare (sector average 64.5) and 1st of 6 in Drug Manufacturers - Specialty & Generic. Scores as of 2026-10-25.
Its strongest lenses are Price (valuation) at 93 (Healthcare average 50) and Quality (profitability) at 93 (Healthcare average 50). Its weakest lenses are Trend (momentum) at 44 (sector average 50) and Industry opportunity at 74 (sector average 81).
| Lens | Type | IRWD | Healthcare average | Drug Manufacturers - Specialty & Generic average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 74 | 81 | 74 | 15th |
| Stock selection | Research signal | 86 | 79 | 76 | 91st |
| KPI momentum | Research signal | 86 | 78 | 71 | 73rd |
| Catalyst watch | Research signal | 77 | 74 | 71 | 72nd |
| Price (valuation) | Fundamental lens | 93 | 50 | 65 | 100th |
| Expansion (growth) | Fundamental lens | 77 | 50 | 39 | 90th |
| Quality (profitability) | Fundamental lens | 93 | 50 | 63 | 100th |
| Trend (momentum) | Fundamental lens | 44 | 50 | 48 | 42nd |
The most recent call analysed was held on 2026-08-06 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -66.6%: its price is well below the path its market, sector and industry moves explain (strongly undervalued versus the model path). Factor sensitivity: market beta 1.60, sector beta 1.00, industry beta -0.21; the factor model explains 10% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Viatris Inc. (VTRS) | 63.7 | B- | -13.1% |
| Teva Pharmaceutical Industries Ltd. ADR (TEVA) | 63.5 | B- | -29.4% |
| United Therapeutics Corp. (UTHR) | 62.5 | B- | -10.5% |
| Haleon plc ADR (HLN) | 60.6 | B- | +4.3% |
| Zoetis Inc. (ZTS) | 51.2 | C | -2.7% |
Ironwood Pharmaceuticals Inc. financial statements · Healthcare sector ranking · Drug Manufacturers - Specialty & Generic industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.